Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic

Human Mutation

Volumn 30, Issue 4, 2009, Pages 661-668

  Polakova, V ^a,b   Pardini, B ^a   Naccarati, A ^a   Landi, S ^c   Slyskova, J ^a   Novotny, J ^b   Vodickova, L ^a,d   Bermejo, J L ^e   Hanova, M ^a   Smerhovsky, Z ^d   Tulupova, E ^a   Kumar, R ^e   Hemminki, K ^e   Vodicka, P ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF PISA   (Italy)

^d NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CDKN1A; CDKN2A; Colorectal cancer susceptibility; CRC; Genetic polymorphisms; Haplotype analysis; TP53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53;

ADULT; ARTICLE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; CZECH REPUBLIC; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; ALLELES; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CZECH REPUBLIC; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63749119744     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20931     Document Type: Article

References (51)

1. Ahmed FE. 2006. Gene-gene, gene-environment and multiple interactions in colorectal cancer. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 24:1-101.
2. Akaike H. 1973. Information theory and an extension of maximum likelihood principle. Second International Symposium on Information Theory. Budapest: Akademiai Kiado. p 267-281.
3. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265.
4. Berggren P, Hemminki K, Steineck G. 2000. p53 Intron 7 polymorphisms in urinary bladder cancer patients and controls. Mutagenesis 15:57-60.
5. Berggren P, Kumar R, Steineck G, Ichiba M, Hemminki K. 2001. Ethnic variation in genotype frequencies of a p53 intron 7 polymorphism. Mutagenesis 16:475-478.
6. Buyru N, Altinisik J, Demokan S, Dalay N. 2007. p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31:207-213.
7. Crawford DC, Nickerson DA. 2005. Definition and clinical importance of haplotypes. Annu Rev Med 56:303-320.
8. Dakouras A, Nikiteas N, Papadakis E, Perakis M, Valis D, Rallis G, Tzanakis N, Peros G, Tsigkris C, Kittas C, Karakitsos P. 2008. P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Res 28:1039-1043.
9. de la Chapelle A. 2004. Genetic predisposition to colorectal cancer. Nat Rev Cancer 4:769-780.
10. Gast A, Bermejo JL, Flohr T, Stanulla M, Burwinkel B, Schrappe M, Bartram CR, Hemminki K, Kumar R. 2007. Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case-control study. Leukemia 21:320-325.
11. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. 2004. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954-1956.
12. Goodman JE, Mechanic LE, Luke BT, Ambs S, Chanock S, Harris CC. 2006. Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer 118:1790-1797.
13. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, Huang CH. 2004. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 13:2217-2224.
14. International HapMap Consortium. 2005. A haplotype map of the human genome. Nature 437:1299-1320.
15. Jung HY, Whang YM, Sung JS, Shin HD, Park BL, Kim JS, Shin SW, Seo HY, Seo JH, Kim YH. 2008. Association study of TP53 polymorphisms with lung cancer in a Korean population. J Hum Genet 53:508-514.
16. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Grieu F, Watanabe G, Iacopetta B. 2006. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 94:593-598.
17. Kemp ZE, Carvajal-Carmona LG, Barclay E, Gorman M, Martin L, Wood W, Rowan A, Donohue C, Spain S, Jaeger E, Evans DG, Maher ER, Bishop T, Thomas H, Houlston R, Tomlinson I. 2006. Colorectal Tumour Gene Identification Study Consortium. Evidence of linkage to chromosome 9q22.33 in colorectal cancer kindreds from the United Kingdom. Cancer Res 66:5003-5006.
18. Khrunin AV, Tarskaia LA, Spitsyn VA, Lylova OI, Bebyakova NA, Mikulich AI, Limborska SA. 2005. p53 polymorphisms in Russia and Belarus: correlation of the 2-1-1 haplotype frequency with longitude. Mol Genet Genomics 272:666-672.
19. Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, Giovannucci EL, Hunter DJ. 2006. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 119:1863-1868.
20. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, Forsti A, Hemminki K, Canzian F, Landi S. 2008. Polymorphisms within micro-RNA binding sites and risk of sporadic colorectal cancer. Carcinogenesis 29:579-584.
21. Malumbres M, Barbacid M. 2001. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222-231.
22. Malumbres M, Barbacid M. 2007. Cell cycle kinases in cancer. Curr Opin Genet Dev 17:60-65.
23. Mammano E, Belluco C, Bonafé M, Olivieri F, Mugianesi E, Barbi C, Mishto M, Cosci M, Franceschi C, Lise M, Nitti D. 2008. Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol May 9 (Epub ahead of print).
24. McCloud JM, Sivakumar R, Greenhough A, Elder J, Jones PW, Deakin M, Elder JB, Fryer AA, Hoban PR. 2004. p16INK4a polymorphism: associations with tumour progression in patients with sporadic colorectal cancer. Int J Oncol 25:1447-1452.
25. Miranda E, Destro A, Malesci A, Balladore E, Bianchi P, Baryshnikova E, Franchi G, Morenghi E, Laghi L, Gennari L, Roncalli M. 2006. Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br J Cancer 95:1101-1107.
26. Mitra S, Sikdar N, Misra C, Gupta S, Paul RR, Roy B, Panda CK, Roychoudhury S. 2005. Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern India. Int J Cancer 117:786-793.
27. Murphy ME. 2006. Polymorphic variants in the p53 pathway. Cell Death Differ 13:916-920.
28. Naccarati A, Pardini B, Hemminki K, Vodicka P. 2007. Sporadic colorectal cancer and individual susceptibility: a review ofthe association studies investigating the role of DNA repair genetic polymorphisms. Mutat Res 635:118-145.
29. Pardini B, Naccarati A, Novotny J, Smerhovsky Z, Vodickova L, Polakova V,Hanova M, Slyskova J, Tulupova E, Kumar R, Bortlik M, Barale R, Hemminki K,Vodicka P. 2008. DNA repair genetic polymorphisms and risk of colorectal cancer in the Czech Republic. Mutat Res 638:146-153.
30. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55:74-108.
31. Pérez LO, Abba MC, Dulout FN, Golijow CD. 2006. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 12:1426-1429.
32. Perfumo C, Bonelli L, Menichini P, Inga A, Gismondi V, Ciferri E, Percivale P, Bianchi Scarrà G, Nasti S, Fronza G, Varesco L. 2006. Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. Digestion 74:228-235.
33. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. 2007. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157-2165.
34. Pietsch EC, Humbey O, Murphy ME. 2006. Polymorphisms in the p53 pathway. Oncogene 25:1602-1611.
35. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH. 2001. Multifactor-dimensionality reduction reveals high-order interactions among estrogen metabolism genes in sporadic breast cancer. Am J Hum Genet 69:138-147.
36. Roh JW, Kim JW, Park NH, Song YS, Park IA, Park SY, Kang SB, Lee HP. 2004. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 93:499-505.
37. Savas S, Ahmad MF, Shariff M, Kim DY, Ozcelik H. 2005. Candidate nsSNPs that can affect the functions and interactions of cell cycle proteins. Proteins 58:697-705.
38. Singh H, Turner D, Xue L, Targownik LE, Bernstein CN. 2006. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA 295:2366-2373.
39. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegård J, Beckman L, Beckman G. 1995. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16:1461-1464.
40. Starinsky S, Figer A, Ben-Asher E, Geva R, Flex D, Fidder HH, Zidan J, Lancet D, Friedman E. 2005. Genotype phenotype correlations in Israeli colorectal cancer patients. Int J Cancer 114:58-73.
41. Stewart BW, Kleihues P, editors. 2003. World Cancer Report. Lyon, France: IARC Press.
42. Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, Chang-Claude J. 2007. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? Pharma-cogenet Genomics 17:639-645.
43. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A, Fielding S, Howarth K, CORGI Consortium, Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R, Thomas H, Peto J, Cazier JB, Houlston R. 2007. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 39:984-988.
44. Vasen HF, Mecklin JP, Khan PM, Lynch HT. 1991. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34:424-425.
45. Vasen HF, Watson P, Mecklin JP, Lynch HT. 1999. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453-1456.
46. Vousden KH, Lu X. 2002. Live or let die: the cell's response to p53. Nat Rev Cancer 2:594-604.
47. Wacholder S. 2004. Bias in intervention studies that enroll patients from high-risk clinics. J Natl Cancer Inst 96:1204-1207.
48. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR. 2002. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94:681-690.
49. Xi YG, Ding KY, Su XL, Chen DF, You WC, Shen Y, Ke Y. 2004. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis 25:2201-2206.
50. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, Olschwang S, Chiang T, Crowdy E, Ferretti V, Laflamme P, Sundararajan S, Roumy S, Olivier JF, Robidoux F, Sladek R, Montpetit A, Campbell P, Bezieau S, O'Shea AM, Zogopoulos G, Cotterchio M, Newcomb P, McLaughlin J, Younghusband B, Green R, Green J, Porteous ME, Campbell H, Blanche H, Sahbatou M, Tubacher E, Bonaiti-Pellié C, Buecher B, Riboli E, Kury S, Chanock SJ, Potter J, Thomas G, Gallinger S, Hudson TJ, Dunlop MG. 2007. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39:989-994.
51. Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu G. 2007. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 37:385-390.